Novartis ( Novartis)

Primary tabs

Novartis's picture

Management

Contact Address

About Novartis

We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.

Novartis press release, blog etc

Tue, 02/11/2025 - 02:51 Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Thu, 11/21/2024 - 15:39 Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Thu, 08/22/2024 - 09:17 Novartis employs creative deal structure to establish Borealis Biosciences divests legacy Chinook site, invests to form new company and engages in R&D collaboration
Thu, 05/16/2024 - 20:41 Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
Wed, 05/15/2024 - 11:04 Novartis highlights pioneering innovation in CML with data from Scemblix Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
Fri, 05/10/2024 - 14:48 Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML
Sat, 05/04/2024 - 04:35 Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
Mon, 02/19/2024 - 00:39 Novartis Appoints Sloan Simpson as Global Head of Investor Relations
Wed, 11/09/2022 - 13:49 Prostate cancer and support of the care partner Carl and Arlenes story
Mon, 11/07/2022 - 03:19 Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
Wed, 09/21/2022 - 01:27 Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya (fingolimod) dosing regimen patent
Sat, 09/10/2022 - 03:20 Novartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial
Thu, 09/01/2022 - 23:33 Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
Wed, 08/31/2022 - 23:27 Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis
Tue, 08/30/2022 - 16:26 Novartis presents new data in breast and prostate cancer at ESMO
Mon, 08/15/2022 - 03:57 Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
Mon, 07/25/2022 - 02:09 Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Thu, 06/30/2022 - 07:47 New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy